Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hybrigenics SA

This article was originally published in Start Up

Executive Summary

The Institut Pasteur, France's leading private medical research institution, has licensed some of its functional proteomics technology to Hybrigenics SA and houses the start-up on its campus, providing it with various technology support functions. Hybrigenics is using automated functional proteomics systems for research into infectious diseases and cancer.

You may also be interested in...



Institut Pasteur

The 125-year old Institut Pasteur has never relied entirely on state funding: today, only a third of its €174 million ($170 million) budget comes from the health and research ministries. In part due to changes instituted in the last two years, license fees and the exploitation of the Pasteur trademark now provide about 45% of Pasteur's budget-with €72 million generated in 2001. And the efforts of the Institute to do technology transfer have resulted in the creation of nine start-ups in the past four years.

Proteomics: Business or Add-On?

Advocates of proteomics argue that without an understanding of protein interactions, drug researchers will be attempting to paint Old Masters with an incomplete set of genomic paint-by-number instructions.

Commercializing Rare Disease Therapies Is Getting Tougher

For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC089937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel